...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>American Journal of Cancer Prevention >The Efficacy of Ibrutinib in Two Patients with Chronic Lymphocytic Leukemia: A Case Report
【24h】

The Efficacy of Ibrutinib in Two Patients with Chronic Lymphocytic Leukemia: A Case Report

机译：依鲁替尼在两名慢性淋巴细胞性白血病患者中的疗效：一例报告

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Ibrutinib known as a new development revolution in therapy of lymphoproliferative disorders like in patients with relapsed and refractory CLL. Aim of this study is efficacy of Ibrutinib in patients with CLL. First patient was 86-year-old man had a diagnosis of CLL established in January 2016. Peripheral blood smear showed 128900 WBC cells that 77 percent of it was absolute lymphocyte (99253 cells). He began receiving ibrutinib at daily dose of 140 mg by in 2016. Second patient was 58-year-old man was diagnosed with lymphoprolifirative disorder (CLL) at oncology clinic in January 2014. At diagnosis time, WBC count was 24000 and platelet count was 203000 and hemoglobin was 14.5 g/dl. Ibrutinib hold for two months and she treated with IVIG. After increased platlate count we try with a new policy consist of chlorambucil and procarbazine as a new regimen. She is stable for 9 months and we decide to decrease this combination, gradually. When in treatment of CLL you have limitation in old drug is better try a new class of target drug with low dosage, and increase to the standard dosage step by step. In this case causes drug induced thrombocytopenia.
机译：依鲁替尼是治疗淋巴增生性疾病（例如复发性和难治性CLL患者）的一项新的发展革命。这项研究的目的是依鲁替尼对CLL患者的疗效。首例患者为86岁的男性，于2016年1月确诊为CLL。外周血涂片显示128900个WBC细胞，其中77％是绝对淋巴细胞（99253个细胞）。他于2016年开始接受每日140 mg的依鲁替尼治疗。第二位患者是58岁的男性，2014年1月在肿瘤诊所被诊断出患有淋巴组织增生性疾病（CLL）。在诊断时，WBC计数为24000，血小板计数为203000，血红蛋白为14.5g / dl。依鲁替尼治疗了两个月，她接受了IVIG治疗。在增加铂盐计数后，我们尝试采用由苯丁酸氮芥和卡巴肼作为新疗法的新政策。她的病情稳定了9个月，我们决定逐渐减少这种组合。在治疗CLL时，您对旧药物有局限性，最好尝试使用低剂量的新型目标药物，并逐步增加至标准剂量。在这种情况下会引起药物性血小板减少。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号